Cargando…

Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma

The study aims to explore the diagnostic value of anti-GNA11 autoantibody in esophageal squamous cell carcinoma (ESCC) from multiple levels. Autoantibody against GNA11 with the highest diagnostic performance was screened out from the customized protein microarray. A total of 486 subjects including E...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huimin, Yang, Xiaoang, Sun, Guiying, Yang, Qian, Cui, Chi, Wang, Xiao, Ye, Hua, Dai, Liping, Shi, Jianxiang, Zhang, Jianying, Wang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462091/
https://www.ncbi.nlm.nih.gov/pubmed/34568004
http://dx.doi.org/10.3389/fonc.2021.661043
_version_ 1784572126817157120
author Wang, Huimin
Yang, Xiaoang
Sun, Guiying
Yang, Qian
Cui, Chi
Wang, Xiao
Ye, Hua
Dai, Liping
Shi, Jianxiang
Zhang, Jianying
Wang, Peng
author_facet Wang, Huimin
Yang, Xiaoang
Sun, Guiying
Yang, Qian
Cui, Chi
Wang, Xiao
Ye, Hua
Dai, Liping
Shi, Jianxiang
Zhang, Jianying
Wang, Peng
author_sort Wang, Huimin
collection PubMed
description The study aims to explore the diagnostic value of anti-GNA11 autoantibody in esophageal squamous cell carcinoma (ESCC) from multiple levels. Autoantibody against GNA11 with the highest diagnostic performance was screened out from the customized protein microarray. A total of 486 subjects including ESCC patients and matched normal controls were recruited in the verification and validation phases by using enzyme-linked immunosorbent assay (ELISA). Western blotting analysis was used to verify the ELISA results. Immunohistochemistry (IHC) was used to evaluate GNA11 expression in ESCC tissues and para-tumor tissues. In addition, a bioinformatics approach was adopted to investigate the mRNA expression of GNA11 in ESCC. Results indicated that the level of anti-GNA11 autoantibody in ESCC patients was significantly higher than that in the normal controls, and it can be used to distinguish ESCC patients from normal individuals in clinical subgroups (p < 0.05), as revealed by both ELISA and Western blotting. The receiver operating characteristic (ROC) curve analysis showed that anti-GNA11 autoantibody could distinguish ESCC patients from normal controls with an area under the ROC curve (AUC) of 0.653, sensitivity of 10.96%, and specificity of 98.63% in the verification cohort and with an AUC of 0.751, sensitivity of 38.24%, and specificity of 88.82% in the validation cohort. IHC manifested that the expression of GNA11 can differentiate ESCC tissues with para-tumor tissues (p < 0.05), but it cannot be used to differentiate different pathological grades and clinical stages (p > 0.05). The mRNA expression of GNA11 in ESCC patients and normal controls was different with a bioinformatics mining with The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data in Gene Expression Profiling Interactive Analysis (GEPIA). In summary, anti-GNA11 autoantibody has the potential to be a new serological marker in the diagnosis of ESCC.
format Online
Article
Text
id pubmed-8462091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84620912021-09-25 Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma Wang, Huimin Yang, Xiaoang Sun, Guiying Yang, Qian Cui, Chi Wang, Xiao Ye, Hua Dai, Liping Shi, Jianxiang Zhang, Jianying Wang, Peng Front Oncol Oncology The study aims to explore the diagnostic value of anti-GNA11 autoantibody in esophageal squamous cell carcinoma (ESCC) from multiple levels. Autoantibody against GNA11 with the highest diagnostic performance was screened out from the customized protein microarray. A total of 486 subjects including ESCC patients and matched normal controls were recruited in the verification and validation phases by using enzyme-linked immunosorbent assay (ELISA). Western blotting analysis was used to verify the ELISA results. Immunohistochemistry (IHC) was used to evaluate GNA11 expression in ESCC tissues and para-tumor tissues. In addition, a bioinformatics approach was adopted to investigate the mRNA expression of GNA11 in ESCC. Results indicated that the level of anti-GNA11 autoantibody in ESCC patients was significantly higher than that in the normal controls, and it can be used to distinguish ESCC patients from normal individuals in clinical subgroups (p < 0.05), as revealed by both ELISA and Western blotting. The receiver operating characteristic (ROC) curve analysis showed that anti-GNA11 autoantibody could distinguish ESCC patients from normal controls with an area under the ROC curve (AUC) of 0.653, sensitivity of 10.96%, and specificity of 98.63% in the verification cohort and with an AUC of 0.751, sensitivity of 38.24%, and specificity of 88.82% in the validation cohort. IHC manifested that the expression of GNA11 can differentiate ESCC tissues with para-tumor tissues (p < 0.05), but it cannot be used to differentiate different pathological grades and clinical stages (p > 0.05). The mRNA expression of GNA11 in ESCC patients and normal controls was different with a bioinformatics mining with The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data in Gene Expression Profiling Interactive Analysis (GEPIA). In summary, anti-GNA11 autoantibody has the potential to be a new serological marker in the diagnosis of ESCC. Frontiers Media S.A. 2021-09-10 /pmc/articles/PMC8462091/ /pubmed/34568004 http://dx.doi.org/10.3389/fonc.2021.661043 Text en Copyright © 2021 Wang, Yang, Sun, Yang, Cui, Wang, Ye, Dai, Shi, Zhang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Huimin
Yang, Xiaoang
Sun, Guiying
Yang, Qian
Cui, Chi
Wang, Xiao
Ye, Hua
Dai, Liping
Shi, Jianxiang
Zhang, Jianying
Wang, Peng
Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma
title Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma
title_full Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma
title_fullStr Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma
title_full_unstemmed Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma
title_short Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma
title_sort identification and evaluation of autoantibody to a novel tumor-associated antigen gna11 as a biomarker in esophageal squamous cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462091/
https://www.ncbi.nlm.nih.gov/pubmed/34568004
http://dx.doi.org/10.3389/fonc.2021.661043
work_keys_str_mv AT wanghuimin identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT yangxiaoang identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT sunguiying identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT yangqian identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT cuichi identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT wangxiao identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT yehua identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT dailiping identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT shijianxiang identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT zhangjianying identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma
AT wangpeng identificationandevaluationofautoantibodytoanoveltumorassociatedantigengna11asabiomarkerinesophagealsquamouscellcarcinoma